Overview: Centromere Antibody (Anti-Centromere) TestIntroduction: The Centromere Antibody Test detects antibodies linked to scleroderma, causing skin tightening or joint pain. Following 2023 ACR guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected scleroderma.
Other Names: Anti-Centromere Assay, Scleroderma Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Centromere antibody testing began in the 1980s with scleroderma research. Immunoassays emerged in the 1990s, and by the 2000s, high-sensitivity assays improved diagnostic accuracy.
Purpose: Diagnoses scleroderma, guides treatment, and monitors antibody levels in patients with skin tightening or joint pain.
Test Parameters: 1. Centromere Antibody
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like skin tightening or joint pain, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document skin tightening, joint pain, or family history of scleroderma. Include current medications, especially immunosuppressants or steroids.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses an immunoassay to measure centromere antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm scleroderma, prompting immunosuppressive therapy. Negative results may require additional antibody testing.
Specialist Consultation: Consult a rheumatologist for result interpretation. A dermatologist referral is advised for skin involvement.
Additional Supporting Tests: ANA test, Scl-70 antibody test, or skin biopsy to confirm scleroderma or assess disease extent.
Test Limitations: False negatives may occur with early disease. Results require clinical correlation.
References: ACR Scleroderma Guidelines, 2023; Arthritis and Rheumatology, Denton CP, 2022.
